#United States #New York #Gross Law Firm #Sarepta Therapeutics #ELEVIDYS

Reminder for Sarepta Therapeutics Investors on Class Action

The Gross Law Firm has recently issued a significant notice for shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). As investors may be aware, a class action lawsuit is currently in motion, and the deadline for potential lead plaintiff appointments is fast approaching—specifically, it is set for August 25, 2025. Shareholders who purchased shares of SRPT during the period from June 22, 2023, to June 24, 2025, are particularly encouraged to participate in the legal proceedings associated with this case.

Allegations Against Sarepta

The lawsuit centers on serious allegations regarding Sarepta Therapeutics' operations and disclosures. The court documents claim that the company made materially false and misleading statements and failed to disclose crucial information about its product, ELEVIDYS, a gene therapy treatment for Duchenne Muscular Dystrophy (DMD). Specifically, the allegations focus on these key areas:

1. Safety Risks: It is argued that ELEVIDYS posed significant safety risks to patients, which were not properly communicated to shareholders or the public.
2. Clinical Trial Shortcomings: The trial regimes and protocols carried out in relation to ELEVIDYS reportedly failed to detect severe side effects that patients may experience from the treatment.
3. Regulatory Scrutiny: As a result of the above issues, recruitment and dosing in the ongoing trials for ELEVIDYS may need to be halted, attracting increased regulatory scrutiny.
4. Misleading Statements: The firm's statements regarding the potential benefits and safety of ELEVIDYS have been termed as lacking a reasonable basis, leading to a materially misled investor base.

Next Steps for Investors

Shareholders are advised to act without delay if they wish to be part of the class action. Registration for the class action is straightforward: investors must provide their purchasing information regarding shares during the specified class period. Registering ensures that you will receive updates on the case through a portfolio monitoring tool designed to track the progress of the lawsuit.

To register as a potential lead plaintiff or to find out more about participating in the lawsuit, shareholders can follow this link: Registration Link.

The Gross Law Firm, recognized nationwide for its dedication to protecting investor rights, emphasizes that appointment as a lead plaintiff is not necessary for shareholders to participate in any recovery from the case. Their mission is to hold companies accountable for disseminating misleading information and to recover losses incurred by investors due to fraudulent practices.

The Importance of Participating

Engaging in this class action may provide affected shareholders with avenues for recovering losses resulting from Sarepta's alleged mismanagement and lack of transparency. The firm, headquartered at 15 West 38th Street, 12th floor, New York, NY, has pledged to uphold the highest standards of corporate governance and protect investor rights.

As the class action progresses, impacted investors are encouraged to stay informed and actively participate in safeguarding their interests. The deadline to enroll in the class action is set for August 25, 2025, and it is recommended that investors make this a priority. Failure to register may result in missing an opportunity for recovery should the case prove successful.

For any inquiries, affected shareholders can contact the Gross Law Firm directly at (646) 453-8903. Keeping abreast of developments and participation could be crucial for investors dealing with the ramifications of Sarepta Therapeutics' practices and the ongoing legal challenges.